En español
NIDA

Menu

A Pilot Study of Osmotic-Release Methylphenidate (OROS-MPH) in Initiating and Maintaining Abstinence in Smokers with Attention Deficit Hyperactivity Disorder (ADHD)

Cigarette in ash tray

The primary objective of this study was to evaluate whether OROS-MPH (Concerta), relative to placebo, increases the effectiveness of standard smoking treatment (i.e., nicotine patch and individual smoking cessation counseling) in obtaining prolonged abstinence for smokers with ADHD. The study involved 255 participants, recruited from six sites.

CTN Protocol ID: 
CTN-0029
DSMB ID: 
DSMB-0029
Enrollment Status: 
Completed
ClinicalTrials.gov ID: 
Primary Outcomes Article: 

Winhusen, T., et al. (2010).  Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial.  Journal of Clinical Psychiatry 71 (12): 1680-8.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3151610/

Principal Investigator(s)
Eugene Somoza, M.D., Ph.D
University of Cincinnati/Cin ARC
3210 Jefferson Avenue, Suite 6
Cincinnati, OH 45220
Somoza@carc.uc.edu

Theresa Winhusen, Ph.D.
University of Cincinnati
Addiction Sciences Division
3131 Harvey Avenue, Suite 104
Cincinnati, OH 45229-3006
winhust@ucmail.uc.edu

Available Brochures

Get this Publication

    Blending Initiative

    blending logo

    Formed with SAMHSA to reduce the gap between research results and treatment.